Latest News

Add to Favorites Subscribe Share
newswise-fb-share-

Showing results

110 of 321
Newswise: Immunotherapy-Chemo Combo Based on Work 
of Roswell Park’s Dr. Ben Seon Gets FDA Approval

Article ID: 714657

Immunotherapy-Chemo Combo Based on Work of Roswell Park’s Dr. Ben Seon Gets FDA Approval

Roswell Park Comprehensive Cancer Center

A cancer therapy based on the work of Ben Seon, PhD, at Roswell Park Comprehensive Cancer Center has been approved by the U.S. Food and Drug Administration (FDA) for patients with an aggressive form of non-Hodgkin lymphoma.

Released:
19-Jun-2019 6:05 PM EDT
Open in New Tab
Comment
Newswise: Roswell Park Physician Leads Development of New Multiple Myeloma Imaging Guidelines

Article ID: 714361

Roswell Park Physician Leads Development of New Multiple Myeloma Imaging Guidelines

Roswell Park Comprehensive Cancer Center

Jens Hillengass, MD, Chief of Myeloma at Roswell Park Comprehensive Cancer Center, led an International Myeloma Working Group (IMWG) effort to compile new recommendations for imaging techniques that offer more sensitive and accurate diagnosis and monitoring for patients with multiple myeloma and other plasma-cell disorders.

Released:
13-Jun-2019 2:05 PM EDT
Open in New Tab
Comment
Newswise: ASCO 2019: Favorable Response for Brain Cancer Patients Receiving Combination Therapy With SurVaxM

Article ID: 713799

ASCO 2019: Favorable Response for Brain Cancer Patients Receiving Combination Therapy With SurVaxM

Roswell Park Comprehensive Cancer Center

With their phase II study in patients with aggressive brain cancer now completed, the developers of the cancer immunotherapy SurVaxM report that combination therapy with the vaccine was more effective than standard therapy for nearly all patients.

Released:
3-Jun-2019 4:50 AM EDT
Open in New Tab
Comment
Newswise: Patients’ Own Cells Do the Work in Roswell Park Immunotherapy Study Incorporating Adult Stem Cells

Article ID: 712819

Patients’ Own Cells Do the Work in Roswell Park Immunotherapy Study Incorporating Adult Stem Cells

Roswell Park Comprehensive Cancer Center

A clinical trial underway at Roswell Park Comprehensive Cancer Center will assess a brand-new immunotherapy approach — reprogramming a patient’s blood stem cells to generate a lasting supply of two types of immune cells — in patients with recurrent cancer of the ovaries, fallopian tubes or peritoneum.

Released:
14-May-2019 10:05 AM EDT
Open in New Tab
Comment
Newswise: Researchers Uncover New Role for Tamoxifen in Triple-Negative Breast Cancers

Article ID: 711418

Researchers Uncover New Role for Tamoxifen in Triple-Negative Breast Cancers

Roswell Park Comprehensive Cancer Center

In a new article in JNCI reporting the first known prognostic marker for triple-negative breast cancer, researchers provide evidence that a widely used breast cancer drug, tamoxifen, may be effective against this notoriously aggressive disease subtype.

Released:
16-Apr-2019 11:05 AM EDT
Open in New Tab
Comment
Roswell Logo 2018_RGB.jpg

Article ID: 710507

Use of Oral Contraceptives Protects Against Most-Fatal Types of Ovarian Cancer

Roswell Park Comprehensive Cancer Center

A team from Roswell Park Comprehensive Cancer Center and the University at Buffalo reports that the protective benefit of oral contraceptives is most pronounced with the most aggressive and fatal subtypes of ovarian cancer.

Released:
1-Apr-2019 4:05 AM EDT
Open in New Tab
Comment
Newswise: All in the Timing: Hour of Radiation Treatments Can Affect Mucositis for Patients With Head/Neck Cancers

Article ID: 710513

All in the Timing: Hour of Radiation Treatments Can Affect Mucositis for Patients With Head/Neck Cancers

Roswell Park Comprehensive Cancer Center

New research from Roswell Park Comprehensive Cancer Center reports that timing of radiation treatments can significantly reduce severity of mucositis and its related impacts.

Released:
1-Apr-2019 4:05 AM EDT
Open in New Tab
Comment
Newswise: With Safety Analysis Now Complete, Roswell Park Moves Forward With Expanded Study of CIMAvax

Article ID: 710506

With Safety Analysis Now Complete, Roswell Park Moves Forward With Expanded Study of CIMAvax

Roswell Park Comprehensive Cancer Center

Final results from the first U.S. clinical study of CIMAvax-EGF show that this Cuban immunotherapy is safe and showed promising efficacy as part of a treatment combination with nivolumab in patients with advanced non-small cell lung cancer.

Released:
31-Mar-2019 8:05 AM EDT
Open in New Tab
Comment
Newswise: Roswell Park Presentations at TCT 2019 Focus on Tools for Predicting Patient Outcomes

Article ID: 708506

Roswell Park Presentations at TCT 2019 Focus on Tools for Predicting Patient Outcomes

Roswell Park Comprehensive Cancer Center

Several Roswell Park Comprehensive Cancer Center experts were invited to highlight research and best practices during the TCT/Transplantation and Cellular Therapy Meetings now underway in Houston, Texas.

Released:
21-Feb-2019 3:05 PM EST
Open in New Tab
Comment
Newswise: Roswell Park Comprehensive Cancer Center Named One of America’s Best Employers for Diversity

Article ID: 706513

Roswell Park Comprehensive Cancer Center Named One of America’s Best Employers for Diversity

Roswell Park Comprehensive Cancer Center

Roswell Park Comprehensive Cancer Center has been recognized as one of America’s Best Employers for Diversity 2019. The Buffalo cancer center was ranked 67th among 500 employers and 8th among the 30 employers within the health care sector to be named to the list, which is based on employee surveys.

Released:
15-Jan-2019 12:05 PM EST
Open in New Tab
Comment

Showing results

110 of 321

Chat now!